Loading quotes...

Forecast

The analysts' average price target is €31.68 (+33.11%). The median is €31.68 (+33.11%).

Buy	9
Hold	2
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

ZAI rises after strong half-year results and MSCI inclusion

ZAI’s stock rose 2.9% to HK$1,230 after the company reported revenue of RMB 954m, an increase of almost 400% year on year. The half-year loss narrowed, indicating margin improvement. Inclusion in the MSCI China Index triggers expected purchases by passive funds and broadens the institutional investor base, causing the stock to show strength against the falling Hang Seng. » More on de.investing.com
ZAI stock rises after Bernstein upgrade and speculation over GLM-5.5

ZAI shares climbed 8.4% on Wednesday to HK$1,095 after Bernstein initiated coverage with an “Outperform” and a HK$1,350 price target. The move followed a short-lived leak and withdrawal of documentation for the successor model GLM-5.3, which had already sparked a rally. Additional speculation about a potential flagship GLM-5.5, which JPMorgan expects to be released in August 2026, boosted investor sentiment; rival MiniMax, by contrast, received only a “Market Perform.” » More on de.investing.com
Zai Lab gains EMA orphan drug designation for DLL3‑targeting therapy

The European Medicines Agency granted orphan drug designation to zocilurtatug pelitecan (zoci), Zai Lab’s DLL3‑targeting antibody‑drug conjugate for pulmonary neuroendocrine carcinomas. The decision, backed by the EMA committee’s positive recommendation, reflects unmet need and early clinical data showing durable responses in relapsed or refractory extensive‑stage small cell lung cancer. The designation may bring development incentives and potential market exclusivity for Zai Lab. » More on finance.yahoo.com
Zai Lab shareholders approve all proposals at 2026 annual general meeting

Zai Lab shareholders voted in favor of all resolutions presented at the 2026 annual general meeting, including the re-election of several directors to serve until 2027 and the appointment of KPMG as independent auditors for the 2026 fiscal year. An advisory resolution on board compensation was approved. Shareholders also granted two general authorizations: one to issue or resell up to 10% of the issued ordinary shares/ADS and one to repurchase up to 10% of the issued ordinary shares/ADS until the 2027 annual general meeting. » More on de.investing.com
Zai Lab: president and COO Josh Smiley resigns

Zai Lab said Josh Smiley will resign as president and chief operating officer effective Monday; his last day is next Thursday. Smiley’s duties will be taken over by founder and CEO Samantha Du and other members of the leadership team. Smiley will receive a contractually agreed severance if he signs a customary release; the information comes from an 8‑K filing with the SEC. » More on de.investing.com

Financials

In the last quarter, Zai Lab had revenue of €95.53M and net profit of -€40.73M

(EUR)	September 2026	YoY
Revenue	95.53M	3.43%
Gross profit	50.24M	14.82%
Net profit	-40.73M	32.91%
EBITDA	-40.99M	56.89%

Fundamentals

Metric	Value
Market capitalization	€2.66B
Number of shares	112.81M
52-week high/low	€26.27 - €14.45
Dividends	No
Beta	0.83
P/E ratio	-14.81
PEG ratio	-6.84
P/B ratio	5.34
P/S ratio	7.52

Company profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.